GPR30 predicts poor survival for ovarian cancer

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 465-471

  Smith, Harriet O ^a,c   Arias Pulido, Hugo ^b   Kuo, Dennis Y ^a   Howard, Tamara ^c   Qualls, Clifford R ^c   Lee, Sang Joon ^b   Verschraegen, Claire F ^b   Hathaway, Helen J ^c   Joste, Nancy E ^b   Prossnitz, Eric R ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Epithelial ovarian carcinoma; GPR30; Low malignant potential; Overall survival

Indexed keywords

ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; PROTEIN GPR30; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 67749119671     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.015     Document Type: Article

References (55)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Dinh P., Harnett P., Piccart-Gebhart M.J., and Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit. Rev. Oncol. Hematol. 67 2 (2008) 103-112
3. Kurman R.J., and Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27 (2008) 151-160
4. Plaxe S.C. Epidemiology of low-grade serous ovarian cancer. Am. J. Obstet. Gynecol. 198 459 (2008) e1-e8 discussion 459 e8-9
5. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am. J. Clin. Pathol. 123 Suppl (2005) S13-S57
6. Bonome T., Lee J.Y., Park D.C., Radonovich M., Pise-Masison C., Brady J., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res.. 65 (2005) 10602-10612
7. Prat J., and De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am. J. Surg. Pathol. 26 (2002) 1111-1128
8. Seidman J.D., and Kurman R.J. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am. J. Surg. Pathol. 20 (1996) 1331-1345
9. Singer G., Oldt III R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95 (2003) 484-486
10. Meinhold-Heerlein I., Bauerschlag D., Hilpert F., Dimitrov P., Sapinoso L.M., Orlowska-Volk M., et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24 (2005) 1053-1065
11. Shih Ie M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164 (2004) 1511-1518
12. Hogdall E.V., Christensen L., Hogdall C.K., Blaakaer J., Gayther S., Jacobs I.J., et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol. Rep. 18 (2007) 1051-1059
13. Wong K.K., Lu K.H., Malpica A., Bodurka D.C., Shvartsman H.S., Schmandt R.E., et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int. J. Gynecol. Pathol. 26 (2007) 404-409
14. Bizzi A., Codegoni A.M., Landoni F., Marelli G., Marsoni S., Spina A.M., et al. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. Cancer Res. 48 (1988) 6222-6226
15. al-Timimi A., Buckley C.H., and Fox H. An immunohistochemical study of the incidence and significance of sex steroid hormone binding sites in normal and neoplastic human ovarian tissue. Int. J. Gynecol. Pathol. 4 (1985) 24-41
16. Ho S.M. Estrogen, progesterone and epithelial ovarian cancer. Reprod. Biol. Endocrinol. 1 (2003) 73
17. Filardo E.J., Quinn J.A., Bland K.I., and Frackelton Jr. A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 (2000) 1649-1660
18. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
19. Filardo E.J., and Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab. 16 (2005) 362-367
20. Prossnitz E.R., Arterburn J.B., Smith H.O., Oprea T.I., Sklar L.A., and Hathaway H.J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol. 70 (2008) 165-190
21. Prossnitz E.R., Sklar L.A., Oprea T.I., and Arterburn J.B. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci. 29 (2008) 116-123
22. Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., Joste N.E., et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 196 386 (2007) e1-e9 discussion 386 e9-11
23. Filardo E.J., Graeber C.T., Quinn J.A., Resnick M.B., Giri D., DeLellis R.A., et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12 (2006) 6359-6366
24. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 (2007) 1859-1866
25. Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Porkin D., et al. International Classification of Diseases for Oncology (ICD-0). 3rd ed (2000), World Health Organization, Geneva
26. Collett D. Modeling Survival Data in Medical Research (1994), Chapman & Hall, London
27. Ali S., and Coombes R.C. Estrogen receptor alpha in human breast cancer: occurrence and significance. J. Mammary Gland Biol. Neoplasia 5 (2000) 271-281
28. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 4 (2002) 197-201
29. Conner P., Lundstrom E., and von Schoultz B. Breast cancer and hormonal therapy. Clin. Obstet. Gynecol. 51 (2008) 592-606
30. Hormone replacement therapy and cancer. Gynecol. Endocrinol. 15 (2001) 453-465
31. Allen N.E., Key T.J., Dossus L., Rinaldi S., Cust A., Lukanova A., et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer 15 (2008) 485-497
32. Cohen I., Beyth Y., Altaras M.M., Shapira J., Tepper R., Cardoba M., et al. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Gynecol. Oncol. 67 (1997) 8-15
33. Lukanova A., and Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 98-107
34. Reeves G.K., Pirie K., Beral V., Green J., Spencer E., and Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335 (2007) 1134
35. Modesitt S.C., and van Nagell Jr. J.R. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet. Gynecol. Surv. 60 (2005) 683-692
36. Kiani F., Knutsen S., Singh P., Ursin G., and Fraser G. Dietary risk factors for ovarian cancer: the Adventist Health Study (United States). Cancer Causes Control 17 (2006) 137-146
37. Huncharek M., and Kupelnick B. Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies. Nutr. Cancer 40 (2001) 87-91
38. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur. J. Cancer Prev. 10 (2001) 125-129
39. Woutersz T.B. Benefits of oral contraception: thirty years' experience. Int. J. Fertil. 36 Suppl. 3 (1991) 26-31
40. Medard M.L., and Ostrowska L. [Combined oral contraception and the risk of reproductive organs cancer in women]. Ginekol. Pol. 78 (2007) 637-641
41. Scambia G., Benedetti-Panici P., Ferrandina G., Distefano M., Salerno G., Romanini M.E., et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer 72 (1995) 361-366
42. Vaidya A.P., Parnes A.D., and Seiden M.V. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Curr. Treatm. Opt. Oncol. 6 (2005) 103-114
43. Langdon S.P., Hawkes M.M., Lawrie S.S., Hawkins R.A., Tesdale A.L., Crew A.J., et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br. J. Cancer 62 (1990) 213-216
44. Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med. Oncol. 24 (2007) 39-43
45. Trope C., Marth C., and Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur. J. Cancer 36 Suppl. 4 (2000) S59-S61
46. Ramirez P.T., Schmeler K.M., Milam M.R., Slomovitz B.M., Smith J.A., Kavanagh J.J., et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol. Oncol. 110 (2008) 56-59
47. Fischer O.M., Hart S., Gschwind A., and Ullrich A. EGFR signal transactivation in cancer cells. Biochem. Soc. Trans. 31 (2003) 1203-1208
48. Farley J., Ozbun L.L., and Birrer M.J. Genomic analysis of epithelial ovarian cancer. Cell Res. 18 (2008) 538-548
49. Gershenson D.M., Sun C.C., Lu K.H., Coleman R.L., Sood A.K., Malpica A., et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 108 (2006) 361-368
50. Vivacqua A., Bonofiglio D., Recchia A.G., Musti A.M., Picard D., Ando S., et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol. 20 (2006) 631-646
51. Filardo E.J., Quinn J.A., Frackelton Jr. A.R., and Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 16 (2002) 70-84
52. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2 (2006) 207-212
53. M.K. Dennis, R. Burai, C. Ramesh, W.K. Petrie, S.N. Alcon, T. Nayak, C. A. Bologa, Leitao, E. Brailoiu, E. Deliu, N.J. Dun, L.A. Sklar, H.J. Hathaway, J.B. Arterburn, T.O. Oprea, E.R. Prossnitz. In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009;5:421-7.
54. Albanito L., Lappano R., Madeo A., Chimento A., Prossnitz E.R., Cappello A.R., et al. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect. 116 (2008) 1648-1655
55. Skirnisdottir I., and Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int. J. Oncol. 30 (2007) 727-734